Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. (Q51313041)

3 April 2018

title

Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. (English)

1 reference

3 April 2018

author name string

Ashish Kumar Gupta

1

1 reference

3 April 2018

Akhilesh Kumar Verma

2

1 reference

3 April 2018

Jyotsna Kailashiya

3

1 reference

3 April 2018

Surya Kumar Singh

4

1 reference

3 April 2018

Narender Kumar

5

1 reference

3 April 2018

publication date

5 September 2012

1 reference

3 April 2018

published in

Platelets

1 reference

3 April 2018

volume

23

1 reference

3 April 2018

page(s)

565-570

1 reference

3 April 2018

issue

8

1 reference

3 April 2018

Signaling events underlying thrombus formation

cites work

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Inhibition of calpain blocks platelet secretion, aggregation, and spreading

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

A key role for dense granule secretion in potentiation of the Ca2+ signal arising from store-operated calcium entry in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Ca2+ and pH determine the interaction of chromaffin cell scinderin with phosphatidylserine and phosphatidylinositol 4,5,-biphosphate and its cellular distribution during nicotinic-receptor stimulation and protein kinase C activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Tyrosine phosphorylated c-Cbl regulates platelet functional responses mediated by outside-in signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Intracellular pH in human and experimental hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09537104.2012.721907

10.3109/09537104.2012.721907

21 January 2018

Identifiers

DOI

1 reference

3 April 2018

PubMed ID

22950787

1 reference

3 April 2018